A comparison study of HER2 protein overexpression and its gene status in breast cancer.
CONCLUSION: ISH study should be done in all IHC-equivocal cases (2+) to select patient for targeted therapy. Gene amplification must also be confirmed in IHC-positive cases (3+) to prevent from giving non-effective treatment with possible adverse effects to patient with non-amplified HER2 gene.
PMID: 31427548 [PubMed - in process]
Source: Malaysian Journal of Pathology - Category: Pathology Tags: Malays J Pathol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Genetics | HER2 | Malaysia Health | Pathology | Study